Smoking, p53 Mutation, and Lung Cancer
Reads0
Chats0
TLDR
The epidemiologic connection between tobacco exposure and cancer, the molecular basis of p 53 mutation in lung cancer, and the normal molecular and cellular roles of p53 that are abrogated during lung tumor development and progression are reviewed.Abstract:
This issue marks the 50th anniversary of the release of the U.S. Surgeon General's Report on Smoking and Health. Perhaps no other singular event has done more to highlight the effects of smoking on the development of cancer. Tobacco exposure is the leading cause of cancers involving the oral cavity, conductive airways, and the lung. Owing to the many carcinogens in tobacco smoke, smoking-related malignancies have a high genome-wide burden of mutations, including in the gene encoding for p53. The p53 protein is the most frequently mutated tumor suppressor in cancer, responsible for a range of critical cellular functions that are compromised by the presence of a mutation. Herein, we review the epidemiologic connection between tobacco exposure and cancer, the molecular basis of p53 mutation in lung cancer, and the normal molecular and cellular roles of p53 that are abrogated during lung tumor development and progression as defined by in vitro and in vivo studies. We also consider the therapeutic potential of targeting mutant p53 in a clinical setting based upon the cellular role of mutant p53 and data from genetic murine models.read more
Citations
More filters
Journal ArticleDOI
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong,Zhong-Yi Dong,Wen-Zhao Zhong,Xu-Chao Zhang,Jian Su,Zhi Xie,Si-Yang Liu,Hai-Yan Tu,Hua-Jun Chen,Yue-Li Sun,Qing Zhou,Jin-Ji Yang,Xue-Ning Yang,Jia-Xin Lin,Hong-Hong Yan,Hao-Ran Zhai,Hao-Ran Zhai,Li-Xu Yan,Ri-Qiang Liao,Si-Pei Wu,Yi-Long Wu,Yi-Long Wu +21 more
TL;DR: Evidence is provided that TP53 and KRAS mutation in lung adenocarcinoma may be served as a pair of potential predictive factors in guiding anti-PD-1/PD-L1 immunotherapy.
Journal ArticleDOI
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
TL;DR: Biomarkers reflecting tumor immune microenvironment and tumor cell intrinsic features, such as PD-L1 expression, density of tumor infiltrating lymphocyte (TIL), tumor mutational burden, and mismatch-repair (MMR) deficiency, have been noticed to associate with treatment effect of anti-PD-1/anti-PD.
Journal ArticleDOI
Biomarker development in the precision medicine era: lung cancer as a case study
TL;DR: Efforts at the national level of several countries to tie molecular measurement of samples to patient data via electronic medical records are the future of precision medicine research.
Journal ArticleDOI
Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Yanyan Lou,Lixia Diao,Edwin Roger Parra Cuentas,Warren Denning,Limo Chen,You Hong Fan,Lauren Averett Byers,Jing Wang,Vassiliki A. Papadimitrakopoulou,Carmen Behrens,Jaime Rodriguez,Patrick Hwu,Ignacio I. Wistuba,John V. Heymach,Don L. Gibbons +14 more
TL;DR: The strong association between EMT status and an inflammatory tumor microenvironment with elevation of multiple targetable immune checkpoint molecules warrants further investigation of using EMT as a predictive biomarker for immune checkpoint blockade agents and other immunotherapies in NSCLC and possibly a broad range of other cancers.
Journal ArticleDOI
Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer
Guangbo Liu,Fen Pei,Fengqing Yang,Lingxiao Li,Amit Dipak Amin,Songnian Liu,J. Ross Buchan,William C. Cho +7 more
TL;DR: Recent advances of the relationship between autophagy and apoptosis in NSCLC are reviewed to provide few insights into the discovery of novel pathogenic factors and the development of new cancer therapeutics.
References
More filters
Journal ArticleDOI
The p53 tumour suppressor gene
TL;DR: Current understanding of the p53 tumour suppressor gene function and potential clinical significance is reviewed.
Journal ArticleDOI
Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins
Ruben D. Ramirez,Shelley Sheridan,Luc Girard,Mitsuo Sato,Young Ho Kim,Jon Pollack,Michael Peyton,Ying Zou,Jonathan M. Kurie,J. Michael DiMaio,Sara Milchgrub,Alice L. Smith,Rhonda F. Souza,Rhonda F. Souza,Laura K. Gilbey,Xi Zhang,Kenia Gandia,Melville B. Vaughan,Woodring E. Wright,Adi F. Gazdar,Jerry W. Shay,John D. Minna +21 more
TL;DR: Cytogenetic analysis and array comparative genomic hybridization profiling show immortalized HBECs to have duplication of parts of chromosomes 5 and 20, and microarray gene expression profiling demonstrates that the Cdk4/hTERT-immortalized bronchial cell lines clustered together and with nonimmortalization bronchia cells, distinct from lung cancer cell lines.
Journal ArticleDOI
Genetic mechanisms of tumor suppression by the human p53 gene.
TL;DR: Estimation of the stepwise mutation or loss of both p53 alleles during tumorigenesis suggests that mutation of both alleles of the p53 gene is essential for its role in oncogenesis.
Journal ArticleDOI
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model
TL;DR: A mouse model for neuroendocrine lung tumors is established by conditional inactivation of Rb1 and Trp53 in mouse lung epithelial cells that developed with high incidence aggressive lung tumors with striking morphologic and immunophenotypic similarities to SCLC.
Journal ArticleDOI
Tumor predisposition in mice mutant for p63 and p73: Evidence for broader tumor suppressor functions for the p53 family
Elsa R. Flores,Shomit Sengupta,John B Miller,Jamie J. Newman,Jamie J. Newman,Roderick T. Bronson,Denise Crowley,Denise Crowley,Annie Yang,Frank McKeon,Tyler Jacks,Tyler Jacks +11 more
TL;DR: It is shown here that p63+/-;p73+/- mice develop spontaneous tumors, providing evidence for a broader role for the p53 family than has been previously reported.
Related Papers (5)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi,Naiyer A. Rizvi,Matthew D. Hellmann,Matthew D. Hellmann,Alexandra Snyder,Alexandra Snyder,Pia Kvistborg,Vladimir Makarov,Jonathan J. Havel,William Lee,Jianda Yuan,Phillip Wong,Teresa S. Ho,Martin L. Miller,Natasha Rekhtman,Andre L. Moreira,Fawzia Ibrahim,Cameron Bruggeman,Billel Gasmi,Roberta Zappasodi,Yuka Maeda,Chris Sander,Edward B. Garon,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Ton N. Schumacher,Timothy A. Chan,Timothy A. Chan +28 more
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer,Karen L. Reckamp,Paul Baas,Lucio Crinò,Wilfried Eberhardt,Elena Poddubskaya,Scott J. Antonia,Adam Pluzanski,Everett E. Vokes,Esther Holgado,David M. Waterhouse,Neal Ready,Justin F. Gainor,Osvaldo Arén Frontera,Libor Havel,Martin Steins,Marina Chiara Garassino,Joachim G.J.V. Aerts,Manuel Domine,Luis Paz-Ares,Martin Reck,Christine Baudelet,Christopher T. Harbison,Brian Lestini,David R. Spigel +24 more